Nevertheless, the phase 3 KEYNOTE-062 trial reported conflicting results for the use of PD-L1 as a prognostic or predictive biomarker in gastric adenocarcinoma, since pembrolizumab plus chemotherapy did not improve OS or PFS in patients who had a PD-L1 positivity ≥ 1 or ≥ 10. This evidence concerns the gene CD274 and gastric adenocarcinoma.